Second-line chemotherapy in advanced cancer of the pancreas: A multicenter survey of the Gruppo Oncologico Italia Meridonale on the activity and safety of the folfiri regimen in clinical practice  by Arcara, C. et al.
Abstracts
Gastrointestinal cancer
SECOND-LINE CHEMOTHERAPY IN ADVANCED CANCER OF THE
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LOGICO ITALIA MERIDONALE ON THE ACTIVITY AND SAFETY
OF THE FOLFIRI REGIMEN IN CLINICAL PRACTICE
C. Arcara a, E. Maiello b, Giuliani c, N. Borsellino d, V. Gebbia a, G.
Colucci a. a La Maddalena, University of Palermo, Italy. b IRCSS Cura
Sollievo della Sofferenza, San Giovanni Rotondo, Italy. c Istituto Tumori,
Bari, Italy. dOsp. Buccheri, LaFerla, Palermo, Italy.
Introduction: In daily clinical practice second-line chemother-
apy is frequently given to patients with advanced pancreatic can-
cer failing gemcitabine-based first-line chemotherapy without
solid scientific support.
Patients and methods: A retrospective survey was carried out
including 26 patients pretreated with gemcitabine in monoche-
motherapy or in combination with oxaliplatin. Patients received
standard FOLFIRI regimen biweekly until progression or unac-
ceptable toxicity. FOLFIRI regimen included irinotecan (150
mg/m2 on day 1), leucovorin (20 mg/m2 bolus) before 5-FU
(400 mg/m2 bolus) followed by 22-hour continuous infusion of
600 mg/m2 on days 1–2).
Results: Five partial responses (19%) and eight stabilizations
(31%) were recorded for a tumor growth control rate of 50%. The
median TTP was 4 months (range 2–7 months), and median over-
all survival was 6.5 months (range 3–9 months). A stabilization of
PS and a subjective improvement of cancer-related symptoms
was recorded in 15 patients (57%).
Conclusions: Data presented in this paper support the use of
FOLFIRI regimen in the second-line treatment of APC patients.
However, the use of second-line chemotherapy should be care-
fully proposed to patients with good PS or those who had a good
response to first-line therapy.
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GASTROINTESTINAL STROMAL TUMOURS: TWO CASE REPORTS
P. Camplese, G. Santarelli, A. Pardolesi, T. Iarussi, F. Mucilli, R.
Sacco. Department of Surgery, UO Clinica Chirurgica, Chieti University,
Italy.
Introduction: Gastrointestinal stromal tumours are rare and
characterised by slow growth and with late symptoms. Surgical
removal and the last pharmacological innovations are the only
possible and potentially curative treatments.
Methods: From 1999 to 2007 we observed 3 patients who
received surgical treatment for gastrointestinal stromal tumours
arising in two cases from the stomach and in one case from the
oesophagus. We report one case of a stomach GIST intraoperative
occasional finding, during laparotomy for a perforated diverticu-
litis, and one case of a distal oesophagus GIST causing mild dys-
phagia. The first patient underwent total gastrectomy with
lymphadenectomy and Hartmann’s operation and the second
patient underwent tumour excision with a laparotomic transhia-
tal approach followed by a Nissen fundoplicatio.
Results: No postoperative mortality or major postoperative
complications were observed. Patients are still alive and in good
health.
Conclusion: The cases we report reopen the question of this
pathology which, with further therapeutic innovations, shows a
rather favourable course but requires a diagnosis at early
stages. Moreover, the case of stomach GIST is particularly repre-
sentative for the tumour remarkable size, other symptoms lacking
which delayed diagnosis compared to other gastrointestinal
localizations.
doi:10.1016/j.ejcsup.2008.06.038
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